AngioDynamics, Inc. Sells AngioDynamics, Ltd. to Its Management.

Business Editors & Health/Medical Writers

QUEENSBURY, N.Y. & ENNISCORTHY, County Wexford, Ireland--(BW HealthWire)--Aug. 1, 2000--AngioDynamics, Inc. and AngioDynamics, Ltd. jointly announced the sale by AngioDynamics Inc. of AngioDynamics, Ltd. its Enniscorthy, Republic of Ireland manufacturing facility and operations.

The purchase was by the management of AngioDynamics, Ltd. supported by two of Ireland's leading venture capital companies, Alliance Investment Capital and ICC. AngioDynamics, Inc. is a wholly owned subsidiary of E-Z-EM, Inc. (Amex:EZM.A and EZM.B).

AngioDynamics, Ltd. was established in 1997 to manufacture cardiovascular (cardiology) products, primarily PTCA catheters, coronary stents, and specialized pressure injectors. This state-of-the-art 26,000 square foot facility was specially designed to manufacture both electromechanical injectors and sterile, disposable devices.

AngioDynamics, Inc. has made a strategic decision to exit the cardiovascular market to focus entirely on the interventional radiology market. As a result, the Irish facility and its primary products no longer fit into the strategic plan, and selling the facility is viewed by the management and board of directors as a positive move for both AngioDynamics, Inc. and AngioDynamics, Ltd.

Eamonn Hobbs, President and CEO of AngioDynamics, Inc. stated: "We built the Irish facility in 1997 to support our entry into the cardiovascular marketplace, however, we have since made a strategic decision to exit the cardiovascular marketplace in order to focus entirely on the interventional radiology marketplace. At this juncture it became obvious that the strategic directions of both companies no longer meshed and our individual corporate efforts were being diluted. Selling the Irish facility to its management is the optimal outcome and we wish all of our former colleagues at AngioDynamics, Ltd. the best success in their new endeavor."

"AngioDynamics, Inc. will continue to focus on the global interventional

radiology marketplace by distributing directly from our facility in New York, with direct sales support in Europe and with our United States marketing staff. We announced last week that we have completed a reorganization of our business in Japan. These strategic changes will now allow us to focus the global interventional radiology marketplace."

Andrew Jones, Managing Director of AngioDynamics, Ltd. stated: "Our decision as a management group to purchase our company was based on our belief in the commercial viability of the company as a standalone entity. In the past year we have developed products and markets directly from Ireland. The fact the company is now owned by its management is a clear signal of our commitment to those markets and customers. Our current management staffing and job functions will remain unchanged and our customers and suppliers will be able to do business with us as usual.

"We are delighted to have identified such high profile venture capital companies. Their investment reflects their enthusiasm for the sector and their belief in the company's management team and its products. They also share our commitment to increasing our R&D investment and further developing our markets.

"We currently have a portfolio of cardiovascular products and the proven ability to manufacture these products on an OEM or contract basis. In particular our new HSC135 family of PTCA catheters and stent delivery systems will form the core of our product offerings.

"It is our intention to develop our business on a number of fronts; Firstly, through in-house R&D, to broaden our cardiovascular product family for sale to OEM customers. On the other hand, we plan to develop service offerings ranging from product development to contract manufacturing of complex finished devices and medical equipment.

"We will continue to furnish AngioDynamics, Inc. their requirements for pressure injectors and some disposable products for up to two years. Also, we have the option to use the AngioDynamics company name for this period. We will establish our own distinct corporate identity when we feel it appropriate to do so.

"Our current product portfolio and existing manufacturing contracts will provide a stable platform from which to develop our growth plans and we expect to provide a steady increase in employment levels over the foreseeable future.

"The outcome of our management buy-out is a good one for both companies. We at AngioDynamics, Ltd. can pursue the cardiovascular marketplace and we wish our former colleagues at AngioDynamics, Inc. the very best as they focus on their effort to expand their major presence in the interventional radiology marketplace."

The statements made in this press release contain certain forward-looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations. In addition to matters described in this release, future actions by the FDA, results of pending or future clinical trials, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc. including but not limited to its Form 10-Q for the quarter ended June 3, 2000, as well as its Annual Report on Form 10-K, may affect the actual results achieved by the Company.